{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:34:32Z","timestamp":1792737272520,"version":"4.5.0"},"reference-count":174,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:p>As systemic therapy of metastatic breast cancer improves, CNS involvement is becoming a more widespread problem. This article summarizes the current knowledge regarding the incidence, clinical presentation, diagnosis, prognosis, and treatment of CNS metastases in patients with breast cancer. When available, studies specific to breast cancer are presented; in studies in which many solid tumors were evaluated together, the proportion of patients with breast cancer is noted. On the basis of data from randomized trials and retrospective series, neurosurgery and stereotactic radiosurgery (SRS) may prolong survival in patients with single brain metastases. The treatment of multiple metastases remains controversial, as does the routine use of whole-brain radiotherapy (WBRT) after either surgery or SRS. Although it is widely assumed that chemotherapy is of limited benefit, data from case series and case reports suggest otherwise. WBRT, neurosurgery, SRS, and medical therapy each have a role in the treatment of CNS metastases; however, neurologic symptoms frequently are not fully reversible, even with appropriate therapy. Studies specifically targeted toward this group of patients are needed.<\/jats:p>","DOI":"10.1200\/jco.2004.01.175","type":"journal-article","created":{"date-parts":[[2004,8,30]],"date-time":"2004-08-30T18:33:03Z","timestamp":1093890783000},"page":"3608-3617","source":"Crossref","is-referenced-by-count":601,"title":["CNS Metastases in Breast Cancer"],"prefix":"10.1200","volume":"22","author":[{"given":"Nancy U.","family":"Lin","sequence":"first","affiliation":[{"name":"From the Departments of Medical Oncology and Radiation Oncology, Dana-Farber Cancer Institute; Brigham and Women's Hospital; and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Radiation Oncology, Dana-Farber Cancer Institute; Brigham and Women's Hospital; and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[{"name":"From the Departments of Medical Oncology and Radiation Oncology, Dana-Farber Cancer Institute; Brigham and Women's Hospital; and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930230311"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(02)00032-4"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)04476-0"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198809000-00011"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800701)46:1<162::AID-CNCR2820460127>3.0.CO;2-B"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/73.2.232"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1551::AID-CNCR19>3.0.CO;2-Z"},{"key":"R12","unstructured":"Maki DD, Grossman RI: Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. Am J Neuroradiol 21:1064,2000-1066,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1007\/BF01053937"},{"key":"R14","unstructured":"Carey LA, Ewend MG, Sawyer L, et al: Disproportionate CNS relapse after aggressive neoadjuvant chemotherapy. Breast Cancer Res Treat 69:299,2001,  (abstr 511)"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1007\/BF02967448"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"De la Monte SM, Hutchins GM, Moore GW: Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 76:11,1984-17,","DOI":"10.1016\/0002-9343(84)90738-1"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer . 244:707,712, 1989","DOI":"10.1126\/science.2470152"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1936"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490504"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.3.719"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2722"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 18:2350,2000-2351,","DOI":"10.1200\/JCO.2000.18.11.2349"},{"key":"R27","unstructured":"Burstein HJ, Lieberman G, Slamon DJ, et al: Isolated central nervous system metastases in patients with HER2 overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Breast Cancer Res Treat 82:S50,2003-S51,  (abstr 228)"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11436"},{"key":"R29","unstructured":"Weitzen R, Zach L, Kaufman B, et al: High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 21:316,2002,  (abstr 1936)"},{"key":"R30","unstructured":"Wardley AM, Danson S, Clayton AJ, et al: High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 21:61a,2002,  (abstr 241)"},{"key":"R31","unstructured":"Heinrich B, Brudler O, Siekiera W, et al: Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 22:37,2003,  (abstr 147)"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011132609055"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021967"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1038\/415530a"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07337-3"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1038\/ng1060"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.9.1678"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(02)00035-X"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.3109\/07357900009012181"},{"key":"R44","unstructured":"Davis PC, Hudgins PA, Peterman SB, et al: Diagnosis of cerebral metastases: Double-dose delayed CT vs contrast-enhanced MR imaging. Am J Neuroradiol 12:293,1991-300,"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1177\/028418519503600318"},{"key":"R46","unstructured":"Sze G, Milano E, Johnson C, et al: Detection of brain metastasis: Comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. Am J Neuroradiol 11:785,1990-791,"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006308808769"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050459"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(99)91181-9"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2261010920"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-200111000-00001"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002223220802"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1016\/S0748-7983(95)95176-8"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198410000-00010"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00619-0"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00442-8"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.16.5.521"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.23.2.121"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196503)18:3<298::AID-CNCR2820180306>3.0.CO;2-H"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02967-X"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1978.00500350058012"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(80)90195-9"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(81)90184-X"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006486423827"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410070606"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90226-2"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90558-4"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330605"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X"},{"key":"R71","unstructured":"Iwadate Y, Namba H, Yamaura A: Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res 20:573,2000-577,"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1993.79.2.0210"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.369"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00507-6"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.576"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006490200335"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-000-0333-1"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1996.84.5.0748"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)04379-1"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)85008-5"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00568-6"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00416-2"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021262218151"},{"key":"R84","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90341-R"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03060-2"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00198-4"},{"key":"R87","doi-asserted-by":"crossref","unstructured":"Yan ES, Sneed PK, McDermott MW, et al: Number of brain metastases is not an important prognostic factor for survival following radiosurgery for newly-diagnosed nonmelanoma brain metastases. Int J Radiat Oncol Biol Phys 57:S131,2003-S132,  (abstr 14; suppl)","DOI":"10.1016\/S0360-3016(03)00836-8"},{"key":"R88","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.6.789"},{"key":"R89","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890515)63:10<1962::AID-CNCR2820631016>3.0.CO;2-V"},{"key":"R90","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02770-0"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000064569.18914.DE"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.17.1485"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90762-7"},{"key":"R94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3563"},{"key":"R95","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90098-1"},{"key":"R96","doi-asserted-by":"crossref","unstructured":"Robinson C, Stephans K, Fu P, et al: Impact of initial whole brain radiotherapy (WBRT) in addition to gamma knife radiosurgery (GKSRS) on the neurologic status of patients with newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 57:S326,2003,  (abstr 1109; suppl)","DOI":"10.1016\/S0360-3016(03)01207-0"},{"key":"R97","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00594-7"},{"key":"R98","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02645-1"},{"key":"R99","unstructured":"Batchelor TT, Gatineau MP, Supko JG: Pharmacologic considerations in chemotherapy for brain tumors, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice . Philadelphia, PA, Lippincott Williams & Wilkins, pp 657,2001-677"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.2.695"},{"key":"R101","unstructured":"Doroshow JH: Anthracyclines and anthracenediones, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice . Philadelphia, PA, Lippincott Williams & Wilkins, pp 511,2001-512"},{"key":"R102","doi-asserted-by":"crossref","unstructured":"Yusuf RZ, Duan Z, Lamendola DE, et al: Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1,2003-19,","DOI":"10.2174\/1568009033333754"},{"key":"R103","unstructured":"Baker SD, Wirth M, Statkevich P, et al: Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309,1999-317,"},{"key":"R104","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022592913323"},{"key":"R105","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.147"},{"key":"R106","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006335517191"},{"key":"R107","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1995.83.6.1029"},{"key":"R108","unstructured":"Grem JL: 5-Fluoropyrimidines, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice . Philadelphia, PA, Lippincott Williams & Wilkins, pp 197,2001-198"},{"key":"R109","doi-asserted-by":"crossref","unstructured":"Siddik ZH, Jones M, Boxall FE, et al: Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21:19,1988-24,","DOI":"10.1007\/BF00262732"},{"key":"R110","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(98)00009-8"},{"key":"R111","unstructured":"Stewart DL, Leavens M, Maor M, et al: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42:2472,1982-2479,"},{"key":"R112","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198804000-00013"},{"key":"R113","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050391"},{"key":"R114","unstructured":"Yule SM, Price L, Pearson AD, et al: Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 3:1985,1997-1992,"},{"key":"R115","doi-asserted-by":"crossref","unstructured":"Lesser GJ, Grossman SA, Eller S, et al: The distribution of systemically administered [3H]paclitaxel in rats: A quantitative autoradiographic study. Cancer Chemother Pharmacol 37:173,1995-178,","DOI":"10.1007\/s002800050384"},{"key":"R116","unstructured":"Rowinsky EK, Donehower RC: Antimicrotubule agents, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice . Philadelphia, PA, Lippincott Williams & Wilkins, pp 329,2001-372"},{"key":"R117","unstructured":"Marland M, Gaillard C, Sanderink G, et al: Kinetics distribution, metabolism and excretion of radiolabelled Taxotere (14C-RP 56976) in mice and dogs. Proc Am Assoc Cancer Res 34:393,1993,"},{"key":"R118","unstructured":"Pommier YG, Goldwasser F, Strumberg D: Topoisomerase II inhibitors: Epipodophyllotoxins, acridines, ellipticines, and bisdioxopiperazines, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice . Philadelphia, PA, Lippincott Williams & Wilkins, p 549,2001"},{"key":"R119","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6"},{"key":"R120","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950715)76:2<232::AID-CNCR2820760212>3.0.CO;2-0"},{"key":"R121","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W"},{"key":"R122","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P"},{"key":"R123","doi-asserted-by":"crossref","unstructured":"Zulkowski K, Kath R, Semrau R, et al: Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128:111,2001-113,","DOI":"10.1007\/s00432-001-0303-4"},{"key":"R124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.139"},{"key":"R125","unstructured":"Arena FP, Kurzyna-Solinas A, Treanor S, et al: Efficacy of temozolomide in heavily pre-treated patients with stage IV breast cancer with or without brain metastasis. Proc Am Soc Clin Oncol 22:54,2003,  (abstr 215)"},{"key":"R126","unstructured":"Martinez-Cedillo J, Alvarado A, Lara FU, et al: Temozolomide (TMZ) in metastatic breast cancer (BC) to central nervous system (CNS). Proc Am Soc Clin Oncol 22:88,2003,  (abstr 350)"},{"key":"R127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.140"},{"key":"R128","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200108000-00026"},{"key":"R129","doi-asserted-by":"publisher","DOI":"10.3109\/07357909009012049"},{"key":"R130","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#"},{"key":"R131","doi-asserted-by":"publisher","DOI":"10.1007\/BF00146879"},{"key":"R132","doi-asserted-by":"publisher","DOI":"10.1177\/030089169307900516"},{"key":"R133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.117"},{"key":"R134","doi-asserted-by":"publisher","DOI":"10.1007\/BF01052847"},{"key":"R135","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyg046"},{"key":"R136","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H"},{"key":"R137","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199010000-00015"},{"key":"R138","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(99)00042-6"},{"key":"R139","doi-asserted-by":"crossref","unstructured":"Possinger K, Wagner H, Worst P, et al: Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis: A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 14:31,1991-34,","DOI":"10.1159\/000216941"},{"key":"R140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.129"},{"key":"R141","doi-asserted-by":"crossref","unstructured":"Groen HJ, Smit EF, Haaxma-Reiche H, et al: Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer 29A:1696,1993-1699,","DOI":"10.1016\/0959-8049(93)90107-Q"},{"key":"R142","doi-asserted-by":"publisher","DOI":"10.1159\/000227562"},{"key":"R143","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686244"},{"key":"R144","unstructured":"Lee JS, Pisters KM, Komaki R, et al: Paclitaxel\/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: A preliminary report. Semin Oncol 24:S12-52,1997-S12-55,  (4 suppl 12)"},{"key":"R145","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050225"},{"key":"R146","unstructured":"Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 14:461,1995,  (abstr 1485)"},{"key":"R147","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008354323167"},{"key":"R148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.139"},{"key":"R149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.165"},{"key":"R150","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012226718323"},{"key":"R151","unstructured":"Trudeau ME, Walley B, Yelle L, et al: Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol 21,2002,  (abstr 2031)"},{"key":"R152","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M"},{"key":"R153","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.10.1277"},{"key":"R154","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.438"},{"key":"R155","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1997.87.5.0694"},{"key":"R156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507242930402"},{"key":"R157","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000173"},{"key":"R158","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1574"},{"key":"R159","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, et al: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394,1999-3402,"},{"key":"R160","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg365"},{"key":"R161","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.907"},{"key":"R162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.907"},{"key":"R163","unstructured":"Winer E, Cobleigh M, Dickler M, et al: Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76:S115,2002,  (abstr 445; suppl 1)"},{"key":"R164","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601116"},{"key":"R165","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg151"},{"key":"R166","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601073"},{"key":"R167","unstructured":"Burris HA, Hurwitz H, Dees C, et al: EGF10004: A randomized multicenter, phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016. Breast Cancer Res Treat 82:18,2003,  (abstr 39; suppl 1)"},{"key":"R168","doi-asserted-by":"crossref","unstructured":"Kaplan EH, Jones CM, Berger S: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 22:245,2003,  (abstr 981)","DOI":"10.1200\/jco.2004.22.90140.3006"},{"key":"R169","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.35524"},{"key":"R170","unstructured":"Shin DM, Nemunaitis J, Zinner RG, et al: A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol 20:82A,2001,  (abstr 324)"},{"key":"R171","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005706329630"},{"key":"R172","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005835212246"},{"key":"R173","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.14.4420"},{"key":"R174","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90009-3"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.01.175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:55:18Z","timestamp":1653497718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.01.175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":174,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2004,9,1]]}},"alternative-id":["10.1200\/JCO.2004.01.175"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.01.175","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,1]]}}}